QFW
BCRX icon

QTR Family Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

QTR Family Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
161,082
+4,020
+3% +$36.4K 0.56% 33
2026
Q1 		$1.52M Buy
157,062
+3,000
+2% +$23.3K 0.63% 31
2025
Q4 		$1.01M Sell
154,062
-3,075
-2% -$22.2K 0.44% 46
2025
Q3 		$1.19M Buy
157,137
+5,151
+3% +$42.9K 0.57% 35
2025
Q2 		$1.36M Buy
151,986
+431
+0.3% +$4.01K 0.84% 32
2025
Q1 		$1.14M Buy
+151,555
New +$1.22M 0.86% 32

Other funds holding BCRX

OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CV
Counterweight Ventures Wilmington, North Carolina $201M AUM 35.56% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

QTR Family Wealth's BCRX Position: Q2 2026 in Review

QTR Family Wealth increased its BioCryst Pharmaceuticals (BCRX) stake by 2.6% in Q2 2026, buying an estimated $36.4K and bringing the position to 161,082 shares worth $1.61M. The position accounts for 0.56% of the portfolio, ranked #33.

QTR Family Wealth first reported a position in BCRX in Q1 2025 and has held it in 6 quarters since. 52 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • QTR Family Wealth held 161,082 shares of BioCryst Pharmaceuticals worth $1.61M as of Q2 2026.
  • QTR Family Wealth bought 4,020 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $36.4K.
  • BioCryst Pharmaceuticals made up 0.56% of QTR Family Wealth's portfolio in Q2 2026, its #33 holding.
  • QTR Family Wealth first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 52 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on QTR Family Wealth's 13F filing for Q2 2026, filed 27 Jul 2026.